June 23, 2010

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

First-line gefitinib for patients with advanced non-small-cell lung cancer who were selected on the basis of EGFR mutations improved progression-free survival, with acceptable toxicity, as compared with standard chemotherapy. (UMIN-CTR number, C000000376.)

Me gusta

Guardar

Cite This Study

Maemondo et al. (Wed,) studied this question.

synapsesocial.com/papers/699ffdb052ece5d8a8069226 https://doi.org/https://doi.org/10.1056/nejmoa0909530

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1First-Line Gefitinib for Patients With Advanced Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy2009 · 516 citations
2Prospective Phase II Study of Gefitinib for Chemotherapy-Naïve Patients With Advanced Non–Small-Cell Lung Cancer With Epidermal Growth Factor Receptor Gene Mutations2006 · 505 citations
3Frequency of and variables associated with the EGFR mutation and its subtypes2009 · 186 citations
4Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)2005 · 2,089 citations
5FDA Drug Approval Summary: Gefitinib (ZD1839) (Iressa®) Tablets2003 · 577 citations

Me gusta

Guardar